Published in final edited form as:

Bioorg Med Chem Lett. 2014 November 1; 24(21): 5081–5085. doi:10.1016/j.bmcl.2014.09.001.

2-Guanidinoquinazolines as new inhibitors of the STAT3 pathway

Matthew G. LaPorte^{a,*}, Dimas José da Paz Lima^a, Feng Zhang^a, Malabika Sen^b, Jennifer R. Grandis^{b,c,d}, Daniel Camarco^e, Yun Hua^e, Paul A. Johnston^{c,e}, John S. Lazo^f, Lynn O. Resnick^a, Peter Wipf^{a,c,e}, and Donna M. Huryn^{a,e,*}

^aUniversity of Pittsburgh Chemical Diversity Center, University of Pittsburgh, Pittsburgh, PA 15260, USA

^bDepartment of Otolaryngology, University of Pittsburgh, Pittsburgh, PA 15260, USA

^cUniversity of Pittsburgh Cancer Institute, Pittsburgh, PA 15260, USA

^dDepartment of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, PA 15260, USA

^eDepartment of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15260, USA

^fDepartment of Pharmacology, University of Virginia, Charlottesville, VA 22908, USA

Abstract

Synthesis and SAR investigation of 2-guanidinoquinazolines, initially identified in a high content screen for selective STAT3 pathway inhibitors, led to a more potent analog (**11c**) that demonstrated improved anti-proliferative activity against a panel of HNSCC cell lines.

Keywords

STAT3 pathway; Guanidinoquinazolines; Skraup synthesis; Structure–activity relationships; Cancer cell line screening

Despite recent advances in early detection methods and treatment regimens, cancer continues to be a major health threat, responsible for over 25% of deaths annually in the U.S. alone.¹ Head and neck squamous cell carcinomas (HNSCC) are particularly challenging therapeutic targets² as evidenced by the fact that the monoclonal antibody Cetuximab (Erbix), an epidermal growth factor receptor (EGFR) inhibitor,³ was the only new drug approved for this indication in the last several decades. To address this issue, a wide range of signaling pathways that control cell proliferation have been interrogated as potential therapeutic strategies for HNSCC, including the family of signal transducers and activators of transcription (STATs).^{4–6} STAT3 is a tumor promoting transcription factor that

© 2014 Elsevier Ltd. All rights reserved.

*Corresponding authors. Tel.: +1 412 624 8004 (M.G.L.), +1 412 737 3225 (D.M.H.). mgl12@pitt.edu (M.G. LaPorte), huryn@pitt.edu (D.M. Huryn).

Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.bmcl.2014.09.001>.

has been shown to be constitutively activated in numerous cancers, and suppression of STAT3 leads to inhibition of tumor growth in both in vitro and in vivo experiments. In contrast, the related transcription factor, STAT1, activates genes that promote tumor suppression. Therefore, molecules that selectively inhibit STAT3-mediated pathways with no effect on STAT1 pathways, have the potential to be highly effective anti-tumor agents.

Several small organic molecules that inhibit the STAT3 pathway have been reported in the literature.⁷ One strategy has been to design molecules that directly target the Src homology 2 (SH2) domain in STAT3 (**1–4**, Fig. 1).⁸ Other approaches include focusing on inhibiting kinases operative in the STAT3 pathway, such as Janus activated kinases (JAKs), and identified quinolones, pyridones, and the pyridine carboxamide, sorafenib (**5**, **6** and **7**, respectively, Fig. 1).⁹ Additionally, natural products, including STA-21 (**8**), curcumin (**9**), and cucurbitacin Q (**10**), inhibit the STAT3 pathway; however, specific inhibitory mechanisms are still being elucidated (Fig. 2).^{5b} Finally, anti-sense oligonucleotides (AZD9150) and decoy nucleotides directed at STAT3 also exhibit promising anti-proliferative activities in cellular assays.^{5,10}

By using a high content phenotypic screen (HCS) to identify selective inhibitors of IL-6 induced activation of the STAT3 pathway,¹¹ we identified the quinazoline **11a** (Fig. 3). In Cal33 head and neck tumor cells, **11a** inhibited IL-6-induced STAT3 tyrosine phosphorylation and nuclear translocation ($IC_{50} = 15.7 \mu M$), but had no effect on IFN γ -induced activation of the STAT1 pathway at 50 μM (Fig. 3). Western blot analysis indicated a 69% decrease in phospho-STAT3 (pSTAT3) levels upon treatment of **11a** at 39.6 μM concentration (Fig. 4, A and B). Unlike the JAK inhibitor **6** that displayed nanomolar potencies against both STAT3 and STAT1 (data not shown),¹¹ compound **11a** selectively inhibited STAT3 compared to STAT1 and displayed no effects on JAK1/JAK2 as determined by Western blot analysis (Figs. 3 and 4, panels C and D). In addition, **11a** exhibited anti-proliferative activities (IC_{50} 's = 17–37 μM in four HNSCC cell lines (CAL33, FADU, 686 LN, OSC19, Fig. 3). Examination of the literature and PubChem revealed limited examples of biological effects for this chemotype, and Lipinski and Veber parameters fell into the generally desirable ranges (Fig. 3).^{12–15} While the specific mode of action of **11a** was not determined, its apparent lack of activity in the STAT1 assay likely rules out direct binding to SH2 domains. Furthermore, this hit compound did not exhibit any significant activity against a panel of >80 kinases (data not shown). The promising selectivity for STAT3, the notable anti-proliferative activity and desirable physical properties made this compound an attractive lead structure for further medicinal chemistry optimization, and herein we report the results of these efforts.

Our initial strategy was to incorporate modest structural modifications onto the 2-guanidinoquinazoline core in order to establish preliminary structure-activity relationships. Using established synthetic procedures,¹⁶ the dihydroquinolines **13** were generated through the treatment of the substituted anilines **12** with acetone under modified Skraup conditions (Scheme 1).¹⁷ Conversion to the guanidines **14** occurred by reaction with cyano-guanidine under aqueous acidic conditions.¹⁸ The final products, dihydropyrimidinyl-aminoquinazolines **11a–d**, were formed via thermal cyclodehydrations using mesityl oxide in DMSO. The structure of **11b** was confirmed by X-ray analysis (Scheme 1).¹⁶ In this

subset of analogs (Table 1), it was apparent that structural modification was tolerated and modulated the biological profile; the C6-methyl (**11b**) and C6-,C8-dimethyl (**11c**) analogs exhibited improved potency (4- and 30-fold, respectively) while maintaining selectivity versus STAT1 compared to the original hit **11a**. Unlike **11a**, **11b** and **11d**, which failed to achieve 50% inhibition of IFN γ -induced STAT1 activation at 50 μ M, **11c** exhibited an IC₅₀ of 5.9 μ M for STAT1 but still maintained a good selectivity index (Table 1).

Efforts to examine a simplified pharmacophore focused on the preparation of 2-aminoquinazolines of general structure **17** (Scheme 2). The pivotal 2-chloro intermediate **16** was prepared in three steps¹⁹ and subjected to amination under microwave conditions to provide the corresponding quinazoline derivatives **17a–i**. All of these compounds were devoid of activity and therefore established the importance of quinazoline substitutions as well as the C2-linked nitrogenous heterocycle (Table 2).¹¹

To investigate substituent effects on the pyrimidine, we also synthesized pyrimidinones of general structure **19**. The reaction of guanidines **14** with substituted acetoacetic esters (Scheme 3)^{20,21} afforded the dihydropyrimidinones **19a–t**. Representative compounds in this series and their activities are shown in Table 3. Several substitutions (e.g., entries **19a**, **b**, **g**, **h**) slightly improved potency and selectivity compared to the original hit (**11a**), whereas other substitution patterns (e.g., **19e**, **o**, **p**) completely abolished activity. With the exception of **19p**, all 5,6-dimethylpyrimidinones (**19b**, **19f**, **19l**, **19n**) demonstrated inhibition of pSTAT3 at less than 10 IM concentration and maintained at least a 3-fold selectivity against pSTAT1. All new compounds were fully characterized, and all tested compounds had LC/MS/ELSD purities exceeding 91%.

The ability of the most potent analogs to inhibit the proliferation of a panel of HNSCC cell lines is shown in Table 4. While a strict correlation between STAT3 inhibition and cell growth inhibition potency was not evident, compound **11c**, which exhibited the most potent activity in our STAT3 assays, also displayed the most potent anti-proliferative effects.

In summary, 6-ethoxy-4-methylquinazoline-2-amino-dihydro-trimethylpyrimidine **11a**, a structurally novel, selective inhibitor of STAT3-mediated signaling, was further optimized through three rounds of SAR studies. Modest structural changes established the preferred quinazoline substitutions. Most notably, a 20-fold improvement in STAT3 inhibition, while maintaining selectivity over STAT1, was obtained with the 6,8-dimethyl substituted analog **11c**. More substantial changes to the dihydropyrimidine moiety led to complete loss of activity; however, substitution of the quinazoline with dihydropyrimidinones also retained potency and selectivity. The most promising lead structures, **11b**, **11c**, and **19a** exhibited low-micromolar potency against STAT3, at least a 2-fold selectivity over STAT1, and anti-proliferative activity in the 1–50 μ M range. Additional SAR iterations will be needed to increase the activity of these compounds to the sub-micromolar level; however, **11b**, **11c**, and **19a** represent attractive tool compounds to investigate a kinase- and STAT1-independent downregulation of the STAT3 pathway. Studies on the mechanism of action of this class of compounds as well as the biological data and medicinal chemistry of other STAT3 HCS hits will be reported in due course.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors would like to thank Dr. Steven J. Geib for the X-ray analysis of **11b**, Mr. Pete Chambers for LCMS/ELS analyses, Dr. Tong Ying Shun for data processing, and Ms. Mary Liang and Ms. Shelby Anderson for sample handling, procurement, registration, and distribution. We also thank Drs. Mark Schurdak and D. Lansing Taylor (University of Pittsburgh Specialized Applications Center), Drs. Bill Moore (Leidos), Beverly Teicher (NCI) and Shizuko Sei (Leidos) for their helpful discussions. This project was funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under Chemical Biology Consortium Contract No. HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

References and notes

1. Siegel R, Naishadham D, Jemal A. *Cancer Stat.* 2012; 62:10.
2. Song JI, Grandis JR. *Oncogene.* 2000; 19:2489. [PubMed: 10851047]
3. Specenier P, Vermorken JB. *Biol. Targets Ther.* 2013; 7:77.
4. Hanahan D, Weinberg RA. *Cell.* 2011; 144:646. [PubMed: 21376230]
5. For recent reviews of STAT3 and inhibitors, see: Peyser ND, Grandis JR. *Onco Targets Ther.* 2013; 6:999. [PubMed: 23935373] Lin L, Hutzen B, Zuo M, Ball S, Deangelis S, Foust E, Pandit B, Ihnat MA, Shenoy SS, Kulp S, Li P-K, Li C, Fuchs J, Lin J. *Cancer Res.* 2010; 70:2445. [PubMed: 20215512]
6. (a) Masciocchi D, Gelain A, Villa S, Meneghetti F, Barlocco D. *Future Med. Chem.* 2011; 3:567. [PubMed: 21526897] (b) Walker SR, Frank DA. *JAK-STAT.* 2012; 1:292. [PubMed: 24058786]
7. For recent reviews, see: Siveen KS, Sikka S, Surana R, Dai X, Zhang J, Kumar AP, Tan BKH, Sethi G, Bishayee A. *Biochim. Biophys. Acta.* 1845; 2014:136. Wang X, Crowe PJ, Goldstein D, Yang J-L. *Int. J. Oncol.* 2012; 41:1181. [PubMed: 22842992]
8. (a) Mandal PK, Gao F, Lu Z, Ren Z, Ramesh R, Birtwistle JS, Kaluarachchi KK, Chen X, Bast RC Jr. Liao W, McMurray JS. *J. Med. Chem.* 2011; 54:3549. [PubMed: 21486047] (b) Chen J, Bai L, Bernard D, Nikolovska-Coleska Z, Gomez C, Zhang J, Yi H, Wang S. *ACS Med. Chem. Lett.* 2010; 1:85. [PubMed: 20596242] (c) Haftchenary S, Luchman HA, Jouk AO, Veloso AJ, Page BDG, Cheng XR, Dawson SS, Grinshtein N, Shahani VM, Kerman K, Kaplan DR, Griffin C, Aman AM, Al-awar R, Weiss S, Gunning PT. *ACS Med. Chem. Lett.* 2013; 4:1102. [PubMed: 24900612]
9. (a) Pedranzini L, Dechow T, Berishaj M, Comenzo R, Zhou P, Azare J, Bornmann W, Bromberg J. *Cancer Res.* 2006; 66:9714. [PubMed: 17018630] (b) Swiatek-Machado K, Mieczkowski J, Ellert-Miklaszewska A, Swierk P, Fokt I, Szymanski S, Skora S, Szeja W, Gryniewicz G, Lesyng B, Priebe W, Kaminska B. *Canc. Biol. Ther.* 2012; 13:657. (c) Yang F, Jove V, Buettner R, Xin H, Wu J, Wang Y, Nam S, Xu Y, Ara T, DeClerck YA, Seeger R, Yu H, Jove R. *Cancer Biol. Ther.* 2012; 13:534. [PubMed: 22406995]
10. (a) Hayakawa F, Sugimoto K, Harada Y, Hashimoto N, Ohi N, Naoe T. *Blood Cancer J.* 2013; 3:e166. [PubMed: 24292418] (b) Kim M-J, Nam H-J, Kim H-P, Han S-W, Im S-A, Kim T-Y, Oh D-Y, Bang Y-J. *Cancer Lett.* 2013; 335:145. [PubMed: 23402820]
11. Johnston PA, Sen M, Hua Y, Camarco D, Shun TY, Lazo JS, Grandis JR. *Assay Drug Dev. Technol.* 2014; 12:55. [PubMed: 24127660]
12. (a) Holloway GA, Charman WN, Fairlamb AJ, Brun R, Kaiser M, Kostewicz E, Novellow PM, Parisot JP, Richardson J, Street IP, Watson KG, Baell JB. *Antimicrob. Agents Chemother.* 2009; 53:2824. [PubMed: 19364854] (b) Ciustea M, Silverman JEY, Shudofsky AMD, Ricciardi RP. *J. Med. Chem.* 2008; 51:6563. [PubMed: 18808105] (c) Webb TR, Lvovskiy D, Kim S-A, Ji X-D, Melman N, Linden J, Jacobson KA. *Bioorg. Med. Chem.* 2003; 11:77. [PubMed: 12467710]
13. Pubchem (<http://pubchem.ncbi.nlm.nih.gov>) activity for **11a** indicates 21 active assays (6-confirmatory) in 666 bioassays tested: Down Regulation Insulin Promoter (AID 1628);

- Cytotoxicity MIN6 cells (AID 2122); Cruzain Inhibition (AIDs 1476, 1478); FEN1 Endonuclease inhibition (AIDs 588795, 720498).
14. (a) Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. *Adv. Drug Delivery Rev.* 1997; 23:3.(b) Veber DF, Johnson SR, Cheng H-Y, Smith BR, Ward KW, Kopple KD. *J. Med. Chem.* 2002; 45:2615. [PubMed: 12036371]
 15. Physicochemical Properties were Calculated Using: Maestro 8.5.207-QikProp 2.1. Schrödinger, LLC; New York, NY, USA:
 16. Shikhaliev KS, Falaleev AV, Ermolova GI, Solov'ev AS. *Chem. Heterocycl. Compd.* 2002; 38:210.
 17. Fotie J, Kaiser M, Delfin DA, Manley J, Reid CS, Paris J-M, Wenzler T, Maes L, Mahasenan KV, Li C, Werbovets KA. *J. Med. Chem.* 2010; 53:966. and references cited therein. [PubMed: 20047276]
 18. Brown JP. *J. Chem. Soc.* 1964:3012.
 19. (a) Arienzo R, Cramp S, Dyke HJ, Lockey PM, Norman D, Roach AG, Smith P, Wong M, Wren SP. *Bioorg. Med. Chem. Lett.* 2007; 17:1403. [PubMed: 17178222] (b) Armarego WLF, Smith JIC. *J. Chem. Soc.* 1966:234.
 20. Shikhaliev KS, Falaleev AV, Krylsky DV, Solov'ev AS, Shatalov GV. *Chem. Heterocycl. Compd.* 2002; 38:1368.
 21. Guiles J, Sun X, Critchley IA, Ochsner U, Tregay M, Stone K, Bertino J, Green L, Sabin R, Dean F, Dallmann HG, McHenry CS, Janjic N. *Bioorg. Med. Chem. Lett.* 2009; 19:800. [PubMed: 19109016]

Figure 1.
SH2 targeted phosphopeptide mimetics and JAK inhibitors of the STAT3 pathway.

Figure 2.
Natural product STAT3 inhibitors.

Figure 3.
Guanidinoquinazoline hit **11a**.

Figure 4. Inhibition of STAT3 phosphorylation using Western blot analysis of compound **11a** versus vehicle in interleukin 6 (IL6, 50 ng/mL)-stimulated CAL33 cells (A & B). Compound **11a** did not show any effects on pJAK1/JAK1 (C) or pJAK2/JAK2 (D).

Scheme 1.

Preparation of 2-guanidinoquinazolines **11a-d** and X-ray structure of **11b** (CCDC 1020633).

Scheme 2.
Preparation of 2-aminoquinazolines (**17a–j**).

Scheme 3.

Preparation of 2-aminoquinoxaline dihydropyrimidones (**19a-t**).

Table 1STAT3 and STAT1 Activity of 2-guanidinoquinazolines **11a–d**

Compd#	R ¹	R ²	R ³	STAT3 IC ₅₀ ¹¹ (μM)	STAT1 IC ₅₀ ¹¹ (μM)	SI ^a (STAT1/STAT3)
11a	OEt	H	H	15.7 ± 5.4	>50	>3
11b	Me	H	H	7.9 ± 2.8	>50	>6
11c	Me	H	Me	0.8 ± 0.6	5.9 ± 0.9	>7
11d	H	OEt	H	20.7 ± 3.0	>50	>2

^a Selectivity index ratio.

Table 2Inhibitory potencies of 2-aminoquinazolines (**17a–j**)

Compd#	R	STAT3 ¹¹	STAT1 ¹¹
		IC ₅₀ (μM)	IC ₅₀ (μM)
17a		>30	>30
17b		>30	>30
17c		>30	>30
17d		>30	>30
17e		>30	>30
17f		>30	>30
17g		>30	>30
17h		>30	>30

Compd#	R	STAT3 ^{L1}	STAT1 ^{L1}
		IC ₅₀ (μM)	IC ₅₀ (μM)
17i		>30	>30

Table 3Inhibitory potencies of 2-amino-quinazolinyl-dihydropyridimidones **19a–t**

Compd#	R ¹	R ²	R ³	R ⁴	R ⁵	STAT3 IC ₅₀ ¹¹ (μM)	STAT1 IC ₅₀ ¹¹ (μM)	SI ^b (STAT1/STAT3)
19a	Me	H	Me	Me	H	5.0 ± 1.8	12.1 ± 0.9	>2
19b	Me	H	Me	Me	Me	6.4 ± 1.6	>50	>7
19c	Me	H	Me	Me	Allyl	14.3 ± 0.9	>50	>3
19d	Me	H	Me	Ph	H	11.2 ± 2.1	>50	>4
19e	OEt	H	H	Me	H	>50	>50	–
19f	OEt	H	H	Me	Me	11.7 ± 5.7	>50	>4
19g	OEt	H	H	Ph	H	3.4 ± 0.6	>50	>14
19h	OEt	H	H	Me	Bn	2.7 ± 2.5	>50	>18
19i	OMe	H	H	Me	H	34.9 ± 2.7	>50	>1
19j	OMe	H	H	Me	Bn	34.7 ^a	50	>1
19k	H	Me	H	Me	H	19.1 ± 1.3	39.7 ± 1.6	>1
19l	H	Me	H	Me	Me	10.5 ± 0.2	35.2 ± 1.1	>3
19m	Me	Me	H	Me	H	24.7 ± 0.5	>50	>2
19n	Me	Me	H	Me	Me	10.4 ± 1.3	>50	>4
19o	–OCH ₂ O–		H	Me	H	>50	>50	–
19p	–OCH ₂ O–		H	Me	Me	>50	>50	–
19q	–OCH ₂ O–		H	Ph	H	13.0 ± 1.4	>50	>3
19r	–OCH ₂ O–		H	Me	Bn	>50	>50	–
19t	H	OMe	H	Me	H	33.9 ± 1.8	>50	>1

^a Results from a single experiment.^b Selectivity index ratio.

Table 4

Growth inhibition of selected analogs on HNSCC cell lines 686LN, CAL33, FADU and OSC19

Compd#	686LN IC ₅₀ (μ M)	CAL33 IC ₅₀ (μ M)	FADU IC ₅₀ (μ M)	OSC19 IC ₅₀ (μ M)
11a	37.5 $\pm$ 11.1	29.4 $\pm$ 5.9	18.8 $\pm$ 5.3	17.0 $\pm$ 4.6
11b	49.3 ^a	19.7 $\pm$ 0.5	11.0 $\pm$ 0.1	12.8 $\pm$ 0.9
11c	2.4 $\pm$ 0.6	1.2 $\pm$ 0.3	1.9 $\pm$ 0.1	3.2 $\pm$ 0.4
19a	18.0 $\pm$ 10.4	12.9 $\pm$ 0.9	30.9 $\pm$ 14.9	11.2 ^a
19g	37.8 ^a	11.1 ^a	17.9 ^a	19.0 ^a
19h	43.7 $\pm$ 0.7	>50	27.4 $\pm$ 13.3	>50
6	>5	1.3 $\pm$ 0.4	2.4 $\pm$ 0.6	7.7 $\pm$ 4.7

^aResults from a single experiment.